Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Invested Capital (2016 - 2025)

Historic Invested Capital for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $1.3 billion.

  • Agios Pharmaceuticals' Invested Capital fell 2104.55% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 2104.55%. This contributed to the annual value of $1.5 billion for FY2024, which is 9000.25% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Invested Capital is $1.3 billion, which was down 2104.55% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Invested Capital peaked at $2.3 billion during Q1 2021, and registered a low of $660.5 million during Q2 2024.
  • Its 5-year average for Invested Capital is $1.2 billion, with a median of $1.2 billion in 2022.
  • Per our database at Business Quant, Agios Pharmaceuticals' Invested Capital soared by 26728.51% in 2021 and then tumbled by 4742.5% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Invested Capital (Quarter) stood at $1.3 billion in 2021, then decreased by 14.8% to $1.1 billion in 2022, then dropped by 26.33% to $811.0 million in 2023, then soared by 90.0% to $1.5 billion in 2024, then decreased by 16.65% to $1.3 billion in 2025.
  • Its Invested Capital was $1.3 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.5 billion in Q1 2025.